OVERVIEW

Molecular Tumor Board Series 2020: Part II is organized by Cancer Treatment Centers of America® (CTCA).

Time to Complete: 1 hour

Released: May 21, 2020
Expires: May 21, 2021

Accreditation:
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Morehouse School of Medicine and Cancer Treatment Centers of America. The Morehouse School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement:
The Morehouse School of Medicine designates this enduring activity for a maximum of up to 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent to their participation in the activity.

Description:
A multidisciplinary team discusses treatment options for patients with cancer in a tumor board format based on data collected from patients, such as, genetic/genomic testing, pathology and radiological imaging. Cases discussed include:
• Gastroesophageal junction cancer
• Buccal squamous cell cancer
• Colon cancer
• Urothelial cancer

Educational Objectives:
Upon completion of this activity, participants will be able to:
• Describe the necessary components of an effective molecular tumor board
• Explain how to integrate genomic profiling into oncology treatment plans